Market snapshot: Glenmark Pharmaceuticals Inc., USA, has launched its generic Sugammadex Injection in the United States, targeting an annual market size of approximately $1.6 billion. The injection is bioequivalent and therapeutically equivalent to Merck Sharp & Dohme LLC’s reference drug BRIDION. This launch represents a strategic expansion of Glenmark’s injectable portfolio in the high-margin U.S.…
Browsing: Glenmark
N.J., July 28, 2026 /PRNewswire/ — Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch1 of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Doserapeutically equivalent to the reference listed drug, BRIDION®2 Injection, 100 mg/mL of Merck Sharp & Dohme LLC [NDA 022225]
